Valuation: Cogstate Limited

Market Cap 454M 318M 278M 257M 236M 446M 30.6B 3.06B 1.2B 14.94B 1.19B 1.17B 51.59B P/E 2026 *
27.2x
P/E 2027 * 20x
Enterprise Value 396M 278M 243M 224M 206M 390M 26.74B 2.68B 1.05B 13.06B 1.04B 1.02B 45.09B EV / Sales 2026 *
4.56x
EV / Sales 2027 * 3.73x
Free-Float
54.18%
Yield 2026 *
1.22%
Yield 2027 * 1.53%

Last Transcript: Cogstate Limited

1 day+6.42%
1 week+6.42%
Current month+5.29%
1 month+5.29%
3 months+31.44%
6 months+24.38%
Current year+24.38%
1 month 1.8
Extreme 1.8
1.99
Current year 1.26
Extreme 1.26
1.99
1 year 1
Extreme 1
2.1
3 years 0.55
Extreme 0.553
2.1
5 years 0.55
Extreme 0.553
2.1
10 years 0.14
Extreme 0.14
2.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 1999-12-16
Chief Executive Officer - 2005-11-30
Director of Finance/CFO - 2021-01-31
Director TitleAgeSince
Director/Board Member - 2011-02-28
Chairman 67 2009-11-02
Director/Board Member - 2017-01-19
Change 5-day change 1-year change 3-year change Capi.($)
+6.42%+6.42% - - 328M
-1.07%+0.38%+2.06%+5.66% 50.35B
-2.85%-6.25%+366.61%+573.36% 39.21B
+1.78%+0.73%+32.68%-4.91% 34.52B
+1.98%+4.82%+13.71%+60.39% 34.6B
+0.06%-0.57%+3.35%+27.42% 27.05B
-3.27%-5.67% - - 16.68B
+1.64%+0.45%+70.86%+117.46% 15.11B
+0.29%+3.64%+15.30%+17.80% 13.85B
-1.21%+0.73%+18.02%-30.62% 13.18B
Average +0.25%+0.81%+65.32%+95.82% 27.17B
Weighted average by Cap. -0.52%+0.70%+77.64%+118.69%

Financials

2026 *2027 *
Net sales 86.95M 60.87M 53.21M 49.21M 45.16M 85.46M 5.87B 587M 231M 2.86B 229M 224M 9.89B 102M 71.59M 62.58M 57.87M 53.11M 101M 6.9B 690M 271M 3.37B 269M 263M 11.63B
Net income 16.9M 11.83M 10.34M 9.56M 8.78M 16.61M 1.14B 114M 44.81M 557M 44.43M 43.46M 1.92B 22.92M 16.05M 14.03M 12.97M 11.9M 22.53M 1.55B 155M 60.78M 755M 60.27M 58.95M 2.61B
Net Debt -57.17M -40.03M -34.99M -32.36M -29.69M -56.19M -3.86B -386M -152M -1.88B -150M -147M -6.5B -72.31M -50.63M -44.25M -40.93M -37.55M -71.08M -4.88B -488M -192M -2.38B -190M -186M -8.22B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
26-07-09 US$1.990 +6.42% 2,000
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.670AUD
Average target price
3.540AUD
Spread / Average Target
+32.58%

Quarterly revenue - Rate of surprise